About
A narrow territory, known well.
Bailiwick works in one territory and doesn’t stray from it: how rare and genetic disease gets diagnosed, and how programs move that number.
Bailiwick is the practice of Mitch Bailey. It exists because the gap between a therapy and the patients it was made for is very often a diagnosis gap, and closing that gap is specialist work that rarely has an owner.
Mitch has worked on both sides of the problem: building the data infrastructure that predicts who has a disease, and running the programs that get those people tested. The combination is uncommon. Strategy firms tend to bring forecasting without hands-on diagnostics operations; solo advisers tend to bring relationships without the quantitative methods. Bailiwick brings both. The same person can build the model and run the program.
Experience
-
BioMarin Pharmaceutical
Associate Director, Medical Diagnostics · Global Medical Affairs
Led diagnosis and patient-identification strategy across skeletal dysplasia, metabolic and lysosomal storage disorders, and CNS portfolios.
- Built BioMarin’s first sponsored gene panel programs, from launch to global scale.
- Ran a multi-state newborn screening program, including evidence dossiers and nomination strategy.
- Secured leadership endorsement for a centralized diagnosis strategy spanning research, medical and commercial.
- Helped cut time from first symptom to diagnosis in a childhood neurodegenerative condition from roughly 23 months to about five.
- Developed EHR-embedded diagnosis support and campaign measurement, and managed lab partner diligence and RFPs.
-
Freenome
Biomedical informatics
Established the biomedical informatics function behind Freenome’s ML-driven cancer-detection platform, shaping how EHR, claims and genomic data fed predictive models.
-
Research & open tools
Ongoing
Peer-reviewed work on the clinical utility of gene panels and on newborn sequencing; open informatics tools for variant and gene-panel analysis; diagnosis-rate epidemiology across neurodevelopmental conditions including dup15q, STXBP1 and ReNU syndrome.
Ethos
What Bailiwick believes
The patient is the unit.
Not a visit, a claim or a test order. Every estimate is in people, because every one of them is waiting for an answer.
Commercial and patient interests align here.
A therapy reaches more patients when more patients are diagnosed. Earlier, accurate diagnosis is the rare case where the sponsor’s goal and the family’s goal are the same.
Honesty about uncertainty is a service.
An estimate that admits its range is more useful than a confident one that is wrong. The work stops where the evidence stops, and says so.
Independence & disclosure
Serving sponsors, advocates and public health without conflict.
Bailiwick works with pharma and biotech sponsors, patient organizations and public health stakeholders. Their interests usually align, but not always. A written policy governs how they are kept apart.
- Disclosure. Relevant sponsor relationships are disclosed to advocacy and public health clients before work begins.
- Declining where interests collide. Bailiwick won’t take public health work on a condition in which a paying sponsor has a direct interest, unless that interest is disclosed and accepted in writing.
- No vendor ties. Bailiwick takes no referral fees or commissions from labs, data vendors or patient-finding companies it evaluates or recommends.
- Confidentiality. Client information stays with that client. Methods are general; data and findings are not shared across engagements.
- Clean-room methods. Models and playbooks are built from public sources and Bailiwick’s own work, with a provenance log for every input.
Scope note. Bailiwick provides strategy, analysis and program design. It does not perform testing, operate a laboratory, or provide medical or legal advice.
Talk to the person who’ll do the work.
Every engagement is senior-only. The first conversation is with Mitch directly.
